Cigna Is Newest Payer to Join Growing List of Commercial Plans Covering Avedro’s FDA-Approved Cross-Linking Procedure—133 Million Lives Covered in Total
WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa® drug formulations and the KXL® System used in the treatment of progressive keratoconus. Other health plans recently initiating coverage include Humana, Blue Cross Blue